Drug intelligence / Profile preview

TriaC-18

Development stage: Preclinical
Modality: Hydrogel Systems → Drug Delivery Systems, Small Molecules
Administration: Oral, Subcutaneous

Overview

TriaC-18 is a specific triazine-based hydrogelator designed as an innovative therapeutic platform for the treatment of melanoma. It functions with dual capabilities: as a controlled drug delivery system for anticancer agents like doxorubicin, enhancing their biocompatibility and reducing side effects, and by exhibiting intrinsic inhibitory activity against phosphoinositide 3-kinase (PI3K). PI3K is a key enzyme frequently mutated in cancer and plays a significant role in melanoma progression. TriaC-18 self-assembles into fibrous networks, facilitating its hydrogelation properties. [1, 2, 3, 4, 5]

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)

Beyond the preview

Go deeper on TriaC-18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TriaC-18.

Explore the full profile